Novo Nordisk Raises Forecasts on New Obesity Drug

preview_player
Показать описание
Aug.05 -- Lars Fruergaard Jorgensen, Novo Nordisk chief executive officer, discusses first half earnings results. The Danish drug-maker raised its profit and sales forecasts for the year, reflecting high demand for its new obesity medication. He speaks with Bloomberg's Dani Burger on "Bloomberg Surveillance: Early Edition".
  1. Bloomberg Television
  2. Bloomberg
Рекомендации по теме
Novo Nordisk Raises 0:07:03

Novo Nordisk Raises Forecasts on New Obesity Drug

Business Live: Novo 0:25:51

Business Live: Novo Nordisk raises its forecasts fuelled by high demand for weight loss drugs

Novo Nordisk CEO 0:09:39

Novo Nordisk CEO on Wegovy, Ozempic, Profit Forecast, US Market

Novo Nordisk raises 0:00:53

Novo Nordisk raises 2023 guidance due to stronger GLP-1 sales #NVO #NVOStock #GLP1

Novo Nordisk Stock 0:15:47

Novo Nordisk Stock Is CRASHING And I'm BUYING! | HUGE Upside | NVO Stock Analysis |

Wegovy Raises Profit 0:00:56

Wegovy Raises Profit Forecast to £15.3B #news #health #shorts

Novo Nordisk Stock 0:15:16

Novo Nordisk Stock Tumbles: Here's The Price I Would Buy It $NVO

Mizuho's Jared Holz 0:03:25

Mizuho's Jared Holz on Novo Nordisk: There's not much upside near-term

Is Novo Nordisk 0:08:55

Is Novo Nordisk A No-Brainer Buy After The Recent Crash?

How Ozempic Could 0:09:31

How Ozempic Could Break Denmark's Economy

Weight-Loss Drug Sales 0:02:00

Weight-Loss Drug Sales to Reach $150 Billion Annually?

Is Novo Nordisk 0:08:31

Is Novo Nordisk an Undervalued Stock to Buy Now? | NVO Stock Analysis

Weight-Loss Drug Sales 0:01:53

Weight-Loss Drug Sales Forecasted To Hit $150 Billion By 2030 | Wegovy & Zepbound Lead The Charg...

How Ozempic And 0:19:20

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company

Novo Nordisk's New 0:04:46

Novo Nordisk's New Weight Loss Pill- Amycretin

How weight loss 0:02:31

How weight loss drugs could impact stocks

Novo Nordisk Buys 0:13:12

Novo Nordisk Buys Dicerna For 3.3 Billion!

Is Novo Nordisk 0:18:27

Is Novo Nordisk Stock An Undervalued Buy Near 52 Week Low? | MASSIVE Upside! | NVO Stock Analysis |

Отчетный ролик novo 0:02:12

Отчетный ролик novo nordisk райзодег

Novo Nordisk | 0:01:38

Novo Nordisk | Employer value proposition Princeton kick-off

Novo Nordisk Sees 0:04:38

Novo Nordisk Sees Obesity Drug Fueling Record Profit

Novo Nordisk | 0:01:41

Novo Nordisk | Pushing purpose to a new digital level

Reeves' Vision for 1:36:08

Reeves' Vision for Britain, China Weighs Sale of TikTok US to Musk | The Opening Trade: 01/14/2...

Novo Nordisk’s Shocking 0:06:00

Novo Nordisk’s Shocking Earnings Miss: Is the Growth Giant in Trouble?!

Комментарии
Автор

Can you tell me how can I find your agent in Hong Kong? I have three units, they are all not working only for very short time.

takwahjohnnychan
Автор

Their.profit margins should take a hit for the criminal amount they charge for it in the US

saralist
Автор

This is disheartening to hear about profit margins for this new obesity drug that is so outrageously priced - who can afford $1400/mo? They offer only max $200 in assistance.. really???!!!

traciechristenson